Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro
- PMID: 10227113
- DOI: 10.1016/s0920-9964(98)00146-7
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro
Abstract
The atypical antipsychotic olanzapine has relatively high affinity for a number of neuronal receptors in radioreceptor binding assays. The ability of olanzapine to activate or antagonize a number of neuronal receptors was investigated in vitro, in cell lines transfected selectively with receptor subtypes and in receptor-selective isolated tissue studies. Olanzapine had no agonist activity at any of the receptors examined. However, olanzapine was a potent antagonist of 5-HT-stimulated increases in IP3 in cell lines transfected with 5-HT2A or 5-HT2B receptors with IC50 values of 30-40 nM. Olanzapine weakly blocked 5-HT-induced formation of IP3 in cell lines transfected with 5-HT2c receptors, but in this cell line potently inhibited 5-HT-stimulated [35S]GTP gamma S binding with a Ki value of 15 nM. Olanzapine blocked dopamine-stimulated adenylyl cyclase in rat retina with modest potency (Ki = 69 nM), consistent with its relatively low affinity for dopamine D1 receptors. Olanzapine blocked agonist-induced activities at the muscarinic receptor subtypes M1, M2, M3, and M5 with Ki values of 70, 622, 126, and 82 nM, respectively. In studies using cell lines transfected with muscarinic M4 receptors, olanzapine and the atypical antipsychotic clozapine did not have agonist activities as determined with cAMP inhibition and stimulation assays, arachidonic acid release and [35S]GTP gamma S binding assays. However, olanzapine antagonized agonist-induced effects in muscarinic M4 cells with a Ki value of 350 nM. In isolated tissue studies, olanzapine potently blocked agonist-induced effects at alpha 1-adrenergic and histamine H1 receptors (KB = 9 and 19 nM, respectively). Thus, olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5-HT2B, 5-HT2C, alpha 1-adrenergic and histamine H1 receptors. Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors.
Similar articles
-
The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.Psychopharmacology (Berl). 1999 Jan;141(3):267-78. doi: 10.1007/s002130050834. Psychopharmacology (Berl). 1999. PMID: 10027508
-
Radioreceptor binding profile of the atypical antipsychotic olanzapine.Neuropsychopharmacology. 1996 Feb;14(2):87-96. doi: 10.1016/0893-133X(94)00129-N. Neuropsychopharmacology. 1996. PMID: 8822531
-
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.J Clin Psychiatry. 1997;58 Suppl 10:28-36. J Clin Psychiatry. 1997. PMID: 9265914 Review.
-
Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.Psychopharmacology (Berl). 1996 Mar;124(1-2):87-94. doi: 10.1007/BF02245608. Psychopharmacology (Berl). 1996. PMID: 8935803
-
Olanzapine: a basic science update.Br J Psychiatry Suppl. 1999;(37):36-40. Br J Psychiatry Suppl. 1999. PMID: 10211140 Review.
Cited by
-
Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.Psychopharmacology (Berl). 2006 Jul;186(4):561-71. doi: 10.1007/s00213-006-0368-5. Epub 2006 May 13. Psychopharmacology (Berl). 2006. PMID: 16758241
-
Vinylation of a Secondary Amine Core with Calcium Carbide for Efficient Post-Modification and Access to Polymeric Materials.Molecules. 2018 Mar 13;23(3):648. doi: 10.3390/molecules23030648. Molecules. 2018. PMID: 29534039 Free PMC article.
-
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.Psychopharmacology (Berl). 2013 Apr;226(3):615-22. doi: 10.1007/s00213-012-2935-2. Epub 2012 Dec 13. Psychopharmacology (Berl). 2013. PMID: 23239133 Clinical Trial.
-
Olanzapine: a review of its use in the treatment of bipolar I disorder.CNS Drugs. 2001;15(11):871-904. doi: 10.2165/00023210-200115110-00005. CNS Drugs. 2001. PMID: 11700151 Review.
-
An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm.Behav Pharmacol. 2009 Mar;20(2):184-94. doi: 10.1097/FBP.0b013e32832a8f66. Behav Pharmacol. 2009. PMID: 19322074 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information